Pharmacoeconomic Guidelines: Denmark

Country/Region: Denmark
Published PE Recommendations

The Danish Approach to Standards for Economic Evaluation Methodologies (Manuscript 1997)

Additional Information:

Alban A, Gyldmark M, Pedersen AV, Søgaard J. The Danish Approach to Standards for Economic Evaluation Methodologies. Pharmacoeconomics. 1997 Dec;12(6):627-36.
Abstract in English

Key Features

Type of Guidelines Published PE Recommendations
Title and year of the document The Danish Approach to Standards for Economic Evaluation Methodologies (Manuscript 1997)
Affiliation of authors Danish Hospital Institute, University of Copenhagen, University of Odense
Purpose of the document Provide guidelines for how health economic analyses should be scoped in relation to application for finansial subsidy
Standard reporting format included Provided as a supplementary note
Disclosure None declared
Target audience of funding/ author's interests Individuals responsible for undertaking economic analysis of pharmaceuticals
Perspective Social perspective
Indication Not specified
Target population It should be clearly defined which patients are expected to be treated with the analysed pharmaceutical
Subgroup analysis Not specified
Choice of comparator Not specified
Time horizon All relevant cost and effects should be identified - no specific time frame formulated
Assumptions required Not specified
Preferred analytical technique Implicit CEA/CUA
Costs to be included All relevant cost - direct, indirect and intangable. Indirect and intangable cost should be reported seprately, and valued on if it is considered relevant.
Source of costs Randomised controlled trials, supplemented by long term consequences (models)
Modeling Not specified
Systematic review of evidences Not specified
Preference for effectiveness over efficacy Not specified
Preferred outcome measure Outcome measures relevant to specific treatement recommended (successfull treatments, time without symptoms or pain, life years, quality adjusted life years. Willingness to pay estimates should not be only outcomess but can be used as a supplement
Preferred method to derive utility TTO or SG from a representative sample of the population
Equity issues stated Not specified
Discounting costs Should be done when there are effect and cost consequences over several years. Decisions on discount rate should be made in each analysis and could be focus for sensitivity analysis
Discounting outcomes As for cost
Sensitivity analysis-parameters and range Should be made to show robustness of analysis conclusion on changes in assumptions, valuation, cost, effect and discounting
Sensitivity analysis-methods None specified
Presenting results Recommended structure: 1: main results and resume; 2: Introduction; 3: Data material; 4: Analyses; 5: Results, conclusion and discussion; 6: References; 7: Appendix
Incremental analysis Not specified
Total costs vs effectiveness (cost/effectiveness ratio) Not specified
Portability of results (Generalizability) Not specified
Financial impact analysis Finansical consequences on the health budgets as a consequence of using the product should be provided
Mandatory or recommended or voluntary Voluntary


Alban A, Gyldmark M, Pedersen AV, Søgaard J. The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics. 1997 Dec;12(6):627-36.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now